Johnson & Johnson’s MedTech business posted operational sales growth of 3.6% in the second quarter, reaching $8.93 billion, as weaker Abiomed sales weighed on the unit’s performance.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Johnson & Johnson’s MedTech business posted operational sales growth of 3.6% in the second quarter, reaching $8.93 billion, as weaker Abiomed sales weighed on the unit’s performance.